Nadeen Balousha

Nadeen Balousha

Auto-generated profile, based on publicly available information

Nadeen Balousha

Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
ARAhmed Ramzi
Ahmed Ramzi
SMSubhia Maya
Subhia Maya
NBNadeen Balousha
Nadeen Balousha
HSHaneen Sabet
Haneen Sabet
ASAhmed Samir
Ahmed Samir
MSMostafa Ramzi Shiha
Mostafa Ramzi Shiha
Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) presents significant treatment challenges due to its chronic nature, varied clinical presentations, and rarity. Subcutaneous immunoglobulin (SCIG) has emerged as a maintenance therapy, offering potential advantages in administration and patient experience over the previously recognized intravenous immunoglobulin (IVIG). Methods: We included all clinical studies involving CIDP patients treated with SCIG from eleven databases up to March 2024. Results: 50 clinical studies were included in the systematic review, with 22 involved in the meta-analysis. These studies offer clinical data on around 1400 CIDP patients. Almost all studies considered SCIG a maintenance therapy, with the majority of results suggesting it as a viable substitute that may offer comparable or enhanced advantages. Studies covered aspects such as efficacy, safety, quality of life, practicality, economic evaluation, and patient preference. Meta-analysis showed SCIG significantly improved muscle strength and sensory function, had fewer and milder side effects, reduced relapse rates, and received a strong preference. Conclusions: Findings suggest that SCIG for CIDP maintenance not only provides a more feasible alternative, with economic evaluations showing considerable cost reductions over time, and patient preference for SCIG being pronounced, but may also deliver comparable or superior health outcomes. Ongoing research lines on formulations, techniques, and direct comparative studies are critical to further illuminate, enhance, and expand SCIG's role in treatment.

8 January 2025 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
ARAhmed Ramzi
Ahmed Ramzi
SMSubhia Maya
Subhia Maya
NBNadeen Balousha
Nadeen Balousha
MAMufreh Amin
Mufreh Amin
RPRobert Charles Powell
Robert Charles Powell
MSMostafa Ramzi Shiha
Mostafa Ramzi Shiha
Background: Chronic inflammation has been linked to many psychiatric disorders, and therefore, pertinent anti-inflammatory therapies have been empirically evaluated for management. An enduring example of long-term safety, attainability, and versatility has been pentoxifylline (PTX). PTX is a phosphodiesterase inhibitor that modulates inflammatory mediators and affects most blood components and the blood vessels. Methods: Major databases were systematically searched to identify randomized controlled trials (RCTs) on PTX in psychiatric and neuropsychiatric disorders until September 25, 2024. Results: 21 RCTs were included. Five studies evaluated clinical depression: four on major depressive disorder (MDD) and one on bipolar patients experiencing treatment-resistant depression. PTX significantly reduced depressive symptoms in MDD in the four double-blind, randomized, placebo-controlled trials, with the three studies combining PTX and SSRIs showing statistically significant improvements in response rates. Ten RCTs on cognitive impairment reported beneficial effects, particularly in vascular dementia. Meta-analyses support its efficacy in reducing depressive symptoms, cognitive decline, asthenia, and inflammatory markers. Conclusion: Exploring the effects of PTX on psychiatric and neuropsychiatric conditions has provided considerable support for its utility across various disorders, most notably in moderate to severe major depressive disorder (as adjunctive therapy with SSRIs) and cognitive impairment in vascular dementia (as monotherapy). Relevantly, the potential of PTX across a wide range of conditions might prove beneficial in cases of co-occurrence.

7 May 2025 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ARAhmed Ramzi
Ahmed Ramzi
SMSubhia Maya
Subhia Maya
NBNadeen Balousha
Nadeen Balousha
MAMufreh Amin
Mufreh Amin
RRRovan Ahmed Rouby
Rovan Ahmed Rouby
MSMostafa Ramzi Shiha
Mostafa Ramzi Shiha

24 October 2024 in Inflammation Research
Verified
Journal Article
Open access
PDF file
ARAhmed Ramzi
Ahmed Ramzi
SMSubhia Maya
Subhia Maya
NBNadeen Balousha
Nadeen Balousha
MAMufreh Amin
Mufreh Amin
MSMostafa Ramzi Shiha
Mostafa Ramzi Shiha
Introduction: Pentoxifylline (PTX) affects most blood components and the blood vessels, potentially modulating various conditions. Due to its impact on markers linked to COVID-19 severity, research has explored PTX for acute COVID-19. Following the widespread administration of COVID-19 vaccinations, there has been a notable and consistently growing increase in research focusing on long COVID. Consequently, our examination of relevant acute COVID-19 data shall additionally be contextualized into long COVID research. Methods: Various Databases were searched until July 2024 for all primary clinical studies on Pentoxifylline (PTX) in COVID-19. Results: Studies were on acute infection with SARS-CoV-2 where PTX was an adjuvant to standard therapy for ethical and practical reasons under the circumstance. PTX generally reduced hospitalization duration and improved some inflammatory markers, but its impact on mortality was inconsistent. Adverse events were minimal. Meta-analysis revealed a significant reduction in hospitalization duration. Conclusion: This systematic review and meta-analysis suggest that adding pentoxifylline (PTX) to standard COVID-19 therapy may significantly reduce hospitalization duration and improve some inflammatory markers. However, its impact on mortality rates is inconclusive. Adverse events are minimal. PTX can be favorable as an add-on in managing acute COVID-19 and could reduce the risk of long COVID, as well as assist in managing many of its most common symptoms.

9 June 2026 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
ARAhmed Ramzi
Ahmed Ramzi
MAMufreh Amin
Mufreh Amin
MSMahmoud Samir
Mahmoud Samir
RRRovan Rouby
Rovan Rouby
DEDalia Elnady
Dalia Elnady
AEAmin Mefreh Amin Elkhayat
Amin Mefreh Amin Elkhayat
Background: The study sought to quantify and stratify olfactory dysfunction (OD) in Parkinson's disease (PD) using a brief multi-item tool and to explore demographic and clinical patterns in a broad cohort from Egypt. We conducted a multicentre cross-sectional study across neurology clinics. OD was assessed using Vernetti’s Hyposmia Rating Scale, which was translated into Egyptian, integrated into the study survey, piloted, and psychometrically tested. Analyses included multivariable adjusted models. Results: We enrolled 434 patients with PD. Median age at diagnosis was 55 years (IQR 45 to 62), and two thirds were diagnosed within 1 year of motor symptom onset. Family history of PD (20%) was associated with motor symptoms appearing years earlier. Smoking, however, was associated with a later age. More than half of all patients had OD (58.5%), which was typically gradual and either persistent or worsening. The six-item scale identified 34.3% of OD cases that a single global question would have missed ( p < 0.001). In adjusted models, OD showed only a small association with education. A quarter of patients reported never detecting nearby gas leaks even when alerted. Loss of food-smell distinction closely tracked OD status ( p < 0.001). Most had at least one other non-motor symptom (NMS). Conclusions: A majority of patients had OD. It was the prevailing NMS and correlated with overall burden. PD patients in this cohort had a younger age at disease onset and a high rate of family history linked to an even earlier onset. The interval from initial motor complaints to diagnosis appeared comparable to that reported in advanced healthcare settings worldwide. For hyposmia assessment, the brief scale improved identification and flagged safety risks and quality-of-life implications. The hyposmia-related hazards warrant further investigation to objectively test hazard detection and risk-reduction measures.